Bio-Techne Corp. TECH

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.

Con 14 acciones de TECH (USD 1.014,36) habrías recibido USD 4,48 en dividendos en los últimos 12 meses.

TECH hizo una división de acciones (split) de 4:1 el 30 de noviembre de 2022: cada acción se convirtió en 4. Cambió la cantidad de acciones y su precio, pero no el valor total de la inversión.

• Zacks Investment Research 30 sept

  INCY or TECH: Which Is the Better Value Stock Right Now?

  A comparison of two medical-biomedical and genetics stocks reveals that Incyte (INCY) is the more attractive value investment option. INCY holds a Zacks Rank #2 (Buy) with improving earnings outlook and a Value grade of B, while Techne (TECH) has a Zacks Rank #3 (Hold) and Value grade of D. INCY's lower PEG ratio (2.67 vs 7.53) and P/B ratio (3.94 vs 5.38) suggest better valuation metrics.

  

• Zacks Investment Research 11 sept

  Why Is Techne (TECH) Down 0.1% Since Last Earnings Report?

  Bio-Techne (TECH) reported Q4 adjusted EPS of 52 cents, meeting consensus estimates but declining 1.9% year-over-year. Full-year adjusted EPS of $1.93 increased 0.5% and surpassed consensus by 1%. Q4 revenues of $321.2 million exceeded estimates by 1.26%, though organic growth was modest at 3%. The company improved its balance sheet with cash increasing to $264.7 million and debt declining to $200 million. However, analysts have issued no estimate revisions in the past two months, and the stock carries a Zacks Rank #3 (Hold) with weak growth and momentum scores.

  

• GlobeNewswire Inc. 9 sept

  $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger – AUUD, TECH, CZR and CBAN

  Monteverde & Associates PC is investigating four major merger and acquisition deals to determine if they are fair to shareholders: Auddia's merger with McCarthy Finney (1:1 stock exchange), Bio-Techne's sale to Merck KGaA ($73/share), Caesars Entertainment's sale to Fertitta Gaming ($31/share plus ticking consideration), and Colony Bankcorp's merger with First Reliance Bancshares ($19.75 cash or 0.94 stock exchange).

  

• GlobeNewswire Inc. 4 sept

  Global Multiplex Assays Market 2026 Edition - Consumables Dominate Multiplex Assays with 68% Market Share

  The global multiplex assays market is projected to grow from US$6.8 billion in 2025 to US$12.4 billion by 2030, at a 12.8% CAGR. North America leads with 34% market share, while Asia Pacific is the fastest-growing region at 15.5% CAGR. Consumables dominate with 68% market share, and protein multiplex assays hold 42%. Growth is driven by precision medicine, companion diagnostics, and laboratory automation.

  

• GlobeNewswire Inc. 6 jul

  Halper Sadeh LLC is Investigating Whether ACA, TECH, IRDM, LCII are Obtaining Fair Deals for their Shareholders

  Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential violations of federal securities laws and breaches of fiduciary duties related to their proposed acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be limiting superior competing offers.